Chemical and Mechanical Actions of Drugs Active Group Used in COVID-19 Treatment

  • Suhayla K. Mohammed College of Agriculture, University of Baghdad, Al-Jadriya, Baghdad, Iraq
  • Mzahim M. Taha Kirkuk University, 36001 Kirkuk, Iraq
  • Ekhlass M. Taha Department of Chemistry, College of Science for Women, University of Baghdad, Al-Jadriya, 10071 Baghdad, Iraq
Keywords: COVID-19, drugs active group, mechanical action, lopinavir

Abstract

With the new global outbreak of the novel COVID-19, control and treatment has become critical. There is no medication proven to be effective for the treatment of severe acute respiratory syndrome which is caused by COVID-19 according to the World Health Organization (WHO) reports. Most studies that have been done on this time are clinical trials. Those studies used several drugs like lopinavir, ritonavir, nebulized alpha-interferon and, aminoquinolines.

The mechanism of action is not well known so far. This review studies the metabolites of the tested drugs with different kinds of the viral membrane which merging proteins based on mechanical criteria.

References

Prevention CfDCa (2020) coronavirus disease 2019 (COVID-19) - situation summary.

P. Gautret, J-C. Lagier, P. Parola, V.T. Hoang, L. Meddeb, M. Mailhe, B. Doudier, J. Courjon, V. Giordanengo, V.E. Vieira, H.T. Dupont, S. Honoré, P. Colson, E. Chabrière, B. La Scola, J-M. Rolain, P. Brouqui and D. Raoult, Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, International Journal of Antimicrobial Agents (2020), 105949. https://doi.org/10.1016/j.ijantimicag.2020.105949

T.C. Ho, Y.H. Wang, Y.L. Chen, W.C. Tsai, C.H. Lee, K.P. Chuang, Y.M. Chen, C.H. Yuan, S.Y. Ho, M.H. Yang and Y.C. Tyan, Chloroquine and hydroxychloroquine: efficacy in the treatment of the COVID-19, Pathogens. 10(2) (2021), 217.

L.J. Earp, S.E. Delos, H.E. Park and J.M. White, The many mechanisms of viral membrane fusion proteins, Current Topics in Microbiology and Immunology 285 (2005), 25-66. https://doi.org/10.1007/3-540-26764-6_2

V.C. Chu, L.J. McElroy, V. Chu, B.E. Bauman and G.R. Whittaker, The avian coronavirus infectious bronchitis virus undergoes direct low-pH-dependent fusion activation during entry into host cells, Journal of Virology 80(7) (2006), 3180-3188. https://doi.org/10.1128/jvi.80.7.3180-3188.2006

M. Hoffmann, H. Kleine-Weber, S. Schroeder, N. Krüger, T. Herrler, S. Erichsen, T.S. Schiergens, G. Herrler, N.-H. Wu, A. Nitsche, M.A. Müller, C. Drosten and S. Pöhlmann, SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor, Cell 181 (2020), 271-280. https://doi.org/10.1016/j.cell.2020.02.052

N. Rezaei, COVID-19 and medical biotechnology, Avicenna J. Med. Biotechnol. 12(3) (2020), 139.

N. Dong, X. Yang, L. Ye, K. Chen, EW-C. Chan, M. Yang and S. Chen, Genomic and protein structure modelling analysis depicts the origin and infectivity of 2019-nCoV, a new coronavirus which caused a pneumonia outbreak in Wuhan, China, 2020. bioRxiv:2020.2001.2020.913368. https://doi.org/10.1101/2020.01.20.913368

T.Y. Hu, M. Frieman and J. Wolfram, Insights from nanomedicine into chloroquine efficacy against COVID-19, Nat. Nanotechnol. 15 (2020), 247-249. https://doi.org/10.1038/s41565-020-0674-9

Z. Sahraei, M. Shabani, S. Shokouhi and A. Saffaei, Aminoquinolines against coronavirus disease 2019 (COVID-19): chloroquine or hydroxychloroquine, International Journal of Antimicrobial Agents 55 (2020), 105945.

K. Izawa, Y. Amino, M. Kohmura, Y. Ueda and M. Kuroda, 4.16 - Human–Environment Interactions – Taste, In: Liu H-W., Mander L. (eds.) Comprehensive Natural Products II, Elsevier, Oxford, 2010, pp. 631-671. https://doi.org/10.1016/B978-008045382-8.00108-8

B.A. Aderibigbe and H.E. Mukaya, 7 - Nanobiomaterials Architectured for Improved Delivery of Antimalaria Drugs, In: Holban A.M., Grumezescu A.M. (eds.), Nanoarchitectonics for Smart Delivery and Drug Targeting, William Andrew Publishing, 2016, pp. 169-200. https://doi.org/10.1016/B978-0-323-47347-7.00007-0

D. Zhou, S-M. Dai and Q. Tong, COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression, The Journal of Antimicrobial Chemotherapy 75 (2020), 1667-1670. https://doi.org/10.1093/jac/dkaa114

D.C. Warhurst, J.C. Steele, I.S. Adagu, J.C. Craig and C. Cullander, Hydroxychloroquine is much less active than chloroquine against chloroquine-resistant Plasmodium falciparum, in agreement with its physicochemical properties, J. Antimicrob Chemother 52(2) (2003), 188-193. https://doi.org/10.1093/jac/dkg319

J. Liu, R. Cao, M. Xu, X. Wang, H. Zhang, H. Hu, Y. Li, Z. Hu, W. Zhong and M. Wang, Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro, Cell Discovery 6 (2020), 16-16.

K. Uzunova, E. Filipova, V. Pavlova and T. Vekov, Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2, Biomed Pharmacother. 131 (2020), 110668. https://doi.org/10.1016/j.biopha.2020.110668

R. Wu, L. Wang, HC.D. Kuo et al., An update on current therapeutic drugs treating COVID-19, Curr. Pharmacol. Rep. 6 (2020), 56-70. https://doi.org/10.1007/s40495-020-00216-7

Z. Wang, X. Chen, Y. Lu, F. Chen and W. Zhang, Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment, BioSci. Trends 14 (2020), 64-68.

B. Cao, Y. Wang, D. Wen, W. Liu, J. Wang, G. Fan et al., A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19, N Engl. J. Med. 382 (2020), 1787-1799.

J.F. Chan, Y. Yao, M.L. Yeung, W. Deng, L. Bao, L. Jia, F. Li, C. Xiao, H. Gao, P. Yu, J.P. Cai, H. Chu, J. Zhou, H. Chen, C. Qin and K.Y. Yuen, Treatment with lopinavir/ritonavir or interferon – β1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset, J. Infect. Dis. 212 (2015), 1904-1913. https://doi.org/10.1093/infdis/jiv392

T.P. Sheahan, A.C. Sims, S.R. Leist, A. Schäfer, J. Won, A.J. Brown, S.A. Montgomery, A. Hogg, D. Babusis, M.O. Clarke, J.E. Spahn, L. Bauer, S. Sellers, D. Porter, J.Y. Feng, T. Cihlar, R. Jordan, M.R. Denison and R.S. Baric, Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV, Nat. Commun. 11 (2020), 222. https://doi.org/10.1038/s41467-019-13940-6

M. Costanzo, M.A.R. De Giglio and G.N. Roviello, SARS CoV-2: recent reports on antiviral therapies based on lopinavir/ritonavir, Darunavir/umifenovir, hydroxychloroquine, remdesivir, favipiravir and other drugs for the treatment of the new coronavirus, Curr. Med. Chem. 27 (2020), 4536-4541. https://doi.org/10.2174/0929867327666200416131117

J. Lim, S. Jeon, H.Y. Shin, M.J. Kim, Y.M. Seong, W.J. Lee, K.W. Choe, Y.M. Kang, B. Lee and S.J. Park, Case of the index patient who caused tertiary transmission of coronavirus disease 2019 in Korea: the application of lopinavir/ritonavir for the treatment of COVID-19 pneumonia monitored by quantitative RT-PCR, J. Korean Med. Sci. 35 (2020), e79.

L.H. Calabrese, T. Lenfant and C. Calabrese, Interferon therapy for COVID-19 and emerging infections: Prospects and concerns, Cleveland Clinic Journal of Medicine, 2020. https://doi.org/10.3949/ccjm.87a.ccc066

E. Sallard, F. X. Lescure, Y. Yazdanpanah, F. Mentre and N. Peiffer-Smadja, Type 1 interferons as a potential treatment against COVID-19, Antiviral Research 178 (2020), 104791. https://doi.org/10.1016/j.antiviral.2020.104791

L. Yang, J. Wang, P. Hui, T. O. Yarovinsky, S. Badeti, K. Pham and C. Liu, Potential role of IFN-α in COVID-19 patients and its underlying treatment options, Applied Microbiology and Biotechnology 105(10) (2021), 4005-4015. https://doi.org/10.1007/s00253-021-11319-6

Published
2021-09-29
How to Cite
Mohammed, S. K., Taha, M. M., & Taha, E. M. (2021). Chemical and Mechanical Actions of Drugs Active Group Used in COVID-19 Treatment. Earthline Journal of Chemical Sciences, 6(2), 229-237. https://doi.org/10.34198/ejcs.6221.229237
Section
Articles